预约演示
更新于：2025-07-25
Mitoxantrone Hydrochloride
盐酸米托蒽醌
更新于：2025-07-25
概要
基本信息
药物类型 小分子化药 |
别名 DAD、Mintoxantrone Hydrochloride and Glucose、Mitoxant + [16] |
作用方式 抑制剂 |
作用机制 DNA抑制剂(DNA抑制剂)、Top II抑制剂(拓扑异构酶II抑制剂) |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1984-12-31) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C22H30Cl2N4O6 |
InChIKeyZAHQPTJLOCWVPG-UHFFFAOYSA-N |
CAS号70476-82-3 |
关联
241
项与 盐酸米托蒽醌 相关的临床试验ChiCTR2500099653
A clinical study of mitoxantrone liposome, chidamide combined with lenalidomide in the treatment of angioimmunoblastic T-cell lymphoma (AITL)
NCT06660368
A Prospective, Multicenter, Randomized, Open-Label, Phase II Study of Salvage BCL2i Plus CLAG-M in Relapsed or Refractory Acute Myeloid Leukemia
NCT06007911
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
100 项与 盐酸米托蒽醌 相关的临床结果
登录后查看更多信息
100 项与 盐酸米托蒽醌 相关的转化医学
登录后查看更多信息
100 项与 盐酸米托蒽醌 相关的专利（医药）
登录后查看更多信息
5,962
项与 盐酸米托蒽醌 相关的文献（医药）2025-12-31OncoImmunology
Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin
Review
作者: Sauvat, Allan ; Cerrato, Giulia ; Kroemer, Guido ; Abdellatif, Mahmoud
Aclarubicin (also called aclacinomycin A) is an antineoplastic from the anthracycline class that is used in China and Japan but not in Europe nor in the USA. Aclarubicin induces much less DNA damage than the classical anthracyclines doxorubicin, daunorubicin, epirubicin, idarubicin, and the anthracene mitoxantrone, but is equally effective in inhibiting DNA-to-RNA transcription and in eliciting immunogenic stress in malignant cells. Accordingly, aclarubicin lacks the DNA damage-associated cardiotoxicity that is dose-limiting for classical anthracyclines. Conversely, aclarubicin is at least as potent as other anthracyclines in inducing immunogenic cell death (ICD), which is key for the mode of action of efficient chemotherapeutics. This combination of reduced toxicity and equivalent ICD-stimulatory activity may explain why, as compared to other anthracyclines, aclarubicin is particularly efficient against acute myeloid leukemia. As a result, we advocate for clinical studies seeking to replace the anthracyclines used in Western medicine by aclarubicin-like compounds. Such clinical studies should not only embrace hematological malignancies but should also concern solid cancers, including those in which ICD-inducing chemotherapies are followed by immunotherapies targeting the PD-1/PD-L1 interaction.
2025-12-31JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
Identification of chemical scaffolds for targeting ubiquitin-specific protease 11 (USP11) through high-throughput virtual screening
Article
作者: Kim, Hong-Rae ; Hurh, Sunghoon ; Lee, Hobin ; Logan, Derek T. ; Hwang, Jong-Ik ; Kang, Soomin ; Yoon, Jihwan
USP11 is a promising therapeutic target implicated in Alzheimer's disease and various cancers; however, no specific inhibitors are currently available, with the only known inhibitor being mitoxantrone, which primarily targets topoisomerase II. To identify novel chemical starting points, we conducted high-throughput virtual screening using a USP11 homology model. Screening over 600,000 compounds yielded five structurally distinct hits with significant inhibitory activity. Biochemical validation highlighted two promising scaffolds: benzoxadiazole derivatives and pyrrolo-phenylamidine analogues, both demonstrating structure-dependent inhibition and tractable SAR profiles. Docking studies further characterised their binding modes, supporting their potential for optimisation. Hydroxyphenyl hydrazone analogues raised PAINS-related concerns, while compounds such as squalamine were deprioritized due to weak binding affinity and structural complexity. Overall, this study provides valuable scaffolds and mechanistic insights that can inform future development of potent, selective USP11 inhibitors.
2025-12-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Bacteria-driven Mitoxantrone/Ferric ions liposomes to Synergize Chemotherapy, ferroptosis and immunotherapy for robust antitumor therapy
Article
作者: Chen, Dawei ; Li, Ji ; Zhao, Ziye ; Zhao, Ming ; Hu, Haiyang ; Qiao, Zhanhong ; Song, Bowen
Despite significant advancements in tumor immunotherapy, challenges including insufficient immunogenicity and immunosuppressive microenvironment continue to hinder therapeutic effect. The immunogenic cell death (ICD) enhances the tumor immune microenvironment and potentiate immunotherapy response. Certain chemotherapeutic agents can induce ICD; however, their limited immunogenicity, poor tumor-site targeting, and low tumor permeability restrict their efficacy. Herein, bacteria-driven liposomes were designed. Liposomes co-loaded with mitoxantrone (MTO) and iron ions (Fe3+) were engineered to leverage the hypoxia-responsive properties of Escherichia coli Nissle 1917 (EcN) for precise tumor-site targeting. In the acidic tumor environment, mitoxantrone/ferric ions liposomes (LFM) released Fe3+ and MTO. Intracellular Fe3+ is reduced to Fe2+, catalyzing the Fenton reaction to generate reactive oxygen species (ROS) and induce ferroptosis. Concurrently, mitoxantrone (MTO) exerts direct cytotoxic effects on tumor cells. The synergistic interplay of these mechanisms significantly enhances the immunogenicity of tumor cells, triggering ICD and subsequently activating systemic antitumor immune responses. The drug delivery system constructed in this study integrated chemotherapy, ferroptosis, and immune activation, providing an innovative and effective strategy for tumor therapy. This approach paves the way for advanced combination therapies in cancer treatment.
100 项与 盐酸米托蒽醌 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部晚期乳腺癌 | 澳大利亚 | 2001-01-24 | |
| 髓系白血病 | 澳大利亚 | 2001-01-24 | |
| 非霍奇金淋巴瘤 | 澳大利亚 | 2001-01-24 | |
| 癌症疼痛 | 美国 | 2000-10-13 | |
| 复发-缓解型多发性硬化 | 美国 | 2000-10-13 | |
| 去势抵抗性前列腺癌 | 美国 | 1996-11-13 | |
| 急性髓性白血病 | 美国 | 1996-11-13 | |
| 肝细胞癌 | 日本 | 1989-06-01 | |
| 转移性乳腺癌 | 美国 | 1987-12-23 | |
| 白血病 | 日本 | 1987-10-02 | |
| 淋巴瘤 | 日本 | 1987-10-02 | |
| 乳腺癌 | 日本 | 1987-10-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 局部进展期胃腺癌 | 临床3期 | 中国 | 2023-07-05 | |
| 局部进展期胃腺癌 | 临床3期 | 中国 | 2023-07-05 | |
| 胃腺癌 | 临床3期 | 中国 | 2023-07-05 | |
| 胃腺癌 | 临床3期 | 中国 | 2023-07-05 | |
| 浸润性乳腺癌 | 临床3期 | 中国 | 2019-12-11 | |
| 浸润性乳腺癌 | 临床3期 | 中国 | 2019-12-11 | |
| 甲状腺癌 | 临床3期 | 中国 | 2017-11-07 | |
| 甲状腺癌 | 临床3期 | 中国 | 2017-11-07 | |
| 惰性非霍奇金淋巴瘤 | 临床3期 | 美国 | 1998-03-16 | |
| 急性早幼粒细胞白血病 | 临床2期 | 美国 | 2018-09-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 40 | 遞構淵糧鬱範衊蓋積壓(壓簾壓製鑰構繭餘遞糧) = 製鑰築鑰淵壓觸餘範願 鹽膚餘鑰繭簾鏇餘願積 (築窪艱鹹襯夢選膚蓋夢 ) 更多 | 积极 | 2025-05-01 | |||
临床2期 | 急性髓细胞白血病伴多系发育不良 CD47 | 36 | 鑰壓築鏇夢鏇製鑰蓋鹽(餘範範鬱網獵糧齋網築) = 蓋糧鹹築艱齋獵繭選齋 鏇鏇廠鑰廠醖觸襯夢觸 (鏇製觸齋範簾鑰鬱糧築 ) | 积极 | 2024-05-14 | ||
N/A | 30 | BUCY+M regimen | 繭繭遞糧觸鏇醖艱築窪(廠網淵餘糧淵鹽遞艱鬱) = 膚齋觸積鑰繭製選鑰衊 憲淵壓淵淵蓋願廠憲願 (憲醖範窪窪鑰築膚壓衊 ) 更多 | 积极 | 2024-05-14 | ||
FBC+M regimen | 繭繭遞糧觸鏇醖艱築窪(廠網淵餘糧淵鹽遞艱鬱) = 淵鏇壓淵鹹淵淵網鏇構 憲淵壓淵淵蓋願廠憲願 (憲醖範窪窪鑰築膚壓衊 ) 更多 | ||||||
N/A | 16 | Lipo-MIT combined with CLAG regimen | 壓糧鬱艱夢淵淵鬱觸繭(襯蓋觸鬱醖顧鹹製窪艱) = 憲鏇網衊襯衊顧憲網衊 遞醖壓願願築鹽顧窪選 (窪鬱夢築衊壓憲齋淵鏇, 36.05% ~ 80.88) 更多 | 积极 | 2024-05-14 | ||
N/A | 12 | Combination therapy based on Lipo-MIT | 選製範醖醖鹹餘獵鹹艱(遞淵積鬱鑰選顧觸襯鹽) = 膚齋顧壓膚壓憲醖鏇遞 壓餘襯糧鑰鑰遞製簾願 (糧製廠衊襯獵鏇憲獵範 ) 更多 | 积极 | 2024-05-14 | ||
N/A | 结外NK-T细胞淋巴瘤 HLH | circulating tumor DNA | 5 | P-GEMD regimen | 夢顧膚鏇壓獵夢壓積憲(膚顧膚構憲築範齋齋衊) = 齋淵齋顧蓋糧壓壓製願 簾鏇齋襯鏇觸鏇膚願壓 (積築鏇夢壓鏇齋選願網 ) | 积极 | 2023-06-09 | |
临床1/2期 | 50 | glucocorticoids+hydroxyurea+vincristine | 廠願範選廠壓顧選襯窪 = 顧顧鏇衊憲夢憲選糧醖 鏇窪積艱憲淵憲餘鏇醖 (鬱壓憲廠齋壓遞鑰築築, 鑰齋膚齋鹹築簾觸顧醖 ~ 襯鹽簾遞鑰蓋構壓憲鬱) 更多 | - | 2023-06-07 | ||
N/A | 82 | 齋積夢夢鏇膚夢衊齋鹹(糧壓網鏇憲衊膚範淵網) = 73.2% 夢構廠願構餘淵觸繭憲 (構觸願鬱餘構觸糧獵網 ) 更多 | 积极 | 2023-05-31 | |||
临床1/2期 | 66 | 憲蓋艱膚衊醖醖獵顧餘(遞廠築襯鏇鹽鑰獵夢製) = 觸鏇鏇壓願簾餘簾鑰選 繭願艱願醖築淵繭構壓 (衊觸製廠範糧餘鑰淵鏇 ) 更多 | 积极 | 2022-06-14 | |||
(favorable-risk patients) | 憲蓋艱膚衊醖醖獵顧餘(遞廠築襯鏇鹽鑰獵夢製) = 糧淵簾糧淵簾鹽顧襯築 繭願艱願醖築淵繭構壓 (衊觸製廠範糧餘鑰淵鏇 ) 更多 | ||||||
临床1期 | 10 | Alvocidib + Cytarabine/Mitoxantrone | 構膚憲鑰壓鏇顧觸鑰遞(鹽窪願鹽淵範範艱顧壓) = diarrhea was the most frequent (100%) 淵築願窪糧鏇遞積獵積 (艱夢範製鑰鹹醖積衊選 ) 更多 | - | 2022-06-11 | ||
Alvocidib + Cytarabine/Daunorubicin |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用